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ABSTRACT
Murine leukemia viruses (MuL V) are retroviruses that play important roles in the
study of oncogenes, integration, transcriptional regulation and gene therapy. Mink cell focus-
inducing (MCF) viruses are polytropic MuL V s that by definition infect cells from a wide
variety of species. Their ability to infect human cells and their utility as gene therapy vectors
were not well characterized. To address this issue, primary and immortalized human cells
were tested for their ability to be infected by MCF packaged defective vectors as well as
replication competent MCF virus. A new packaging cell line
, called MP AC , was created to
package defective retroviral vectors in virus paricles with envelope proteins derived from a
Moloney mink cell focus- inducing (Mo-MCF) virus. The cellular tropism of MPAC-
packaged retroviral vectors was the same as replication competent MCF viruses. Testing
various established cell lines showed some human cell lines could be infected with MP AC-
packaged vectors while others canot. In addition, I show that some human cells fully
support MCF virus replication while others either partially or fully restrct MCF virus
replication. This indicates that some human cells express a protein on their surface that acts
as a receptor for MCF virses and allows MCF viral entr. In addition, the human cells that
express a receptor for MCF viral entr did not show any fuher block to viral replication.
An important determinant in the pathogenic phenotye of MCF 247 has been mapped
to the enhancer region of the retrovirallong terminal repeat (L TR). Recombination of
endogenous genetic elements with the 3' porton of env occurs and incorporates unique L TR
sequences. Most strongly pathogenic MCF viruses have a duplication of the enhancer
element found in the L TR.
AKR mice are an inbred strain of mice that develop spontaneous T 
-cell lymphomas
between 6 and 12 months of age. 12-25 % ofMCF induced early lymphomas of AKR mice
show MCF viral integration s near c-myc in an opposite transcriptional orientation. A
replication competent MCF virus containing a bacterial amber suppressor tRNA gene (supF)
was used to investigate the changes in the enhancer region following injection of MCF
containing one enhancer in the L TR. Newborn AKR mice were injected with the supF tagged
replication competent virus and observed for signs ofleukemia development (ruffled fu
lethargy, and tumor development). When these signs were detected, the animals were
sacrificed and DNA was prepared from the isolated tumors. Thirt-one tumors DNA were
analyzed for the presence of supF tagged virus and rearangement of the c-myc locus. Nine
supF tagged proviral L TRs integrated near c-myc from four anmals were PCR amplified
sequenced, and/or cloned. All of the enhancer elements analyzed were derived from pro viruses
that integrated in a reverse orientation with respect to c-myc locus. Two of the isolated
enhancer elements contained only a few base changes whereas the majority contained
duplications of different sizes that encompassed different transcription factor binding sites.
The duplicated enhancer regions contained duplications from 82- 134 bp in lengt. One tumor
contained a proviral enhancer with only 5 bp changes relative to the injected virus. This
suggests that the enhancers need only a few specific base changes relative to the injected virus
to accelerate leukemogenesis. The other three tumors contained proviral enhancers with
varous size duplications and additional transcription factor binding sites. These data suggest
that the injected virus is not pathogenic unless the enhancer region is altered. One proviral
integration site encompassing a duplicated enhancer region and 139 bp of the c-myc gene locus
was PCR amplified, cloned and sequenced. A search of the current transcription factor
database (Transfac 3.3) showed no known transcription factor binding site sequences were
created at the junction of the enhancer duplications. The common motif of L Vb , core NF -
and GRE transcription factor binding sites , described by Golemis at al (57), was conserved
throughout the isolated enhancers. Most of the enhancer elements contained additional NF-
KB and/or GRE sites in close proximity to the conserved L Vb-core region. These results
support the hypothesis that additional NF-KB and/or GRE binding sites cooperatively
interact with the conserved GRE-NF- L Vb-core motif in c-myc induced leukemogenesis. In
addition, two unique families of enhancer duplications were identified. The two families
contained enhancers isolated from different tumors that displayed sequence homology and
transcription factor binding site organization unique to each group.
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CHAPTER I
INTRODUCTION
AKR mice are an inbred strain of laboratory mice that have a high incidence of
spontaneous thymoma (nearly 100%) (134). Genetic studies have shown that disease
induction is linked to the inheritance of endogenous ecotropic provirus (106). These
proviruses though are not the primar cause of disease induction (13 , 17 94).
The causative agent of disease induction is a virus formed by recombination of the
endogenous ecotropic virus with other non-ecotropic endogenous sequences (13
, 17
, 33 , 36, 40, 44, 48, 55, 78 , 94). A recombinant envelope gene gives MCF viruses a
broader host range of cells they can infect (74
, 160). Some of these viruses can infect mink
cells and cause cytopathic foci (48, 64). These virses were named mink cell focus inducing
viruses (MCF) (48 , 64, 65). Cloyd et al tested recombinant MCF viruses as well as
ecotropic and xenotropic virses for the ability to accelerate leukemia in AKR and other
strains of mice (24). Only the MCF viruses were able to accelerate leukemia development
in the strains of mice.
MCF viruses are present and can be routinely isolated from spontaneous tumors of
AK mice (24, 71). When the ecotropic MuLVs Moloney, Friend
, RadLV, and Cas-BR-
are injected into varous strains of mice (AKR HRS/J), MCF 
virses with similar env gene
recombination s can be isolated (24, 59). The reproducible, spontaeous generation of
MCF viruses with similar env gene substitutions suggests a direct role for the MCF env
..-
gene product and/or the receptor that they utilize in the acceleration of leukemia in these
strains of mice.
In a direct demonstration of the role the MCF envelope gene plays in
leukemogenicity, Holland et al (73) made a series of recombinant viruses containing
different portions of the genomes ofMCF 247 and the ecotropic virus Akv. If either the
' ,
'Ii
gp70 portion of the env gene or the L TR from MCF 247 are placed in the genetic context of
Ak it becomes weakly leukemogenic. If both sequences are present in Ak the incidence
of disease is almost as high as with MCF 247. DiFronzo and Holland (38) also made
envelope gene substitutions between MCF 247 and Akv and included a 
supF tRNA as a
molecular tag to follow the virus. They found MCF viruses with Akv envelopes
, when
A. Murine Leukemia Virus Receptors
:11
:1'
I I
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injected into AKJ mice, recombined to form MCF envelopes that maintained the supF
tag. These findings support the hypothesis that the MCF envelope gene is an important
determinant of vir ally induced leukemias.
There are four classes of endogenous murne leukemia viruses (MuL V) (186).
Ecotropic virses primarly infect mouse cells. Xenotropic viruses infect cells from species
other than mouse. Amphotropic viruses infect many species of animal cells including
human. Polytopic viruses are recombinant viruses that replicate in mouse as well as non-
mouse cells. Isolates that induce cytopathic foci on mink lung cell monolayers are named
MCF viruses. Polytopic viruses arise from an endogenous ecotropic virus , recombining
with two or more non-ecotropic endogenous viral sequences (48
, 101 , 133). Each class of
endogenous retrovirus utilizes a different receptor to infect cells (Table 1). When a cell is
productively infected with a virus from one of the MuL V virus classes
, later infection with
a second virus from the same virus class wil be greatly inhibited. The reduced ability of the
second virus to infect a pre-infected cell is termed interference. It is due to newly
synthesized viral envelope proteins binding to newly synthesized receptors in the rough
endoplasmic reticulum or golgi apparatus (95
, 152). These newly synthesized receptors are
unavailable for virus entr at the cell surface. Only receptors utilized by that particular
virs class are blocked, receptors for other classes of virus (if present) are available for !II
other virs groups to utilize (although some cell lines show unique interference patterns
when testing MCF and xenotropic viruses). Although these cellular proteins act as viral
receptors, they are likely to be importnt for normal cellular fuctions as well.
Several cellular proteins have been identified as retroviral receptors (see reviews
(Ill , 184)). Receptors for the four groups of murine tye C retroviruses are known. The
ecotropic receptor is a cationic amino acid transporter (CAT) for arginine
, lysine, and
ornithine (86, 181). The amphotropic receptor, Ram- , is a Pi (inorganic phosphate)
transporter. The receptors for both xenotropic and polytopic MuL Vs are recently cloned
(10, 156, 191). The xenotropic and polytopic retrovirus receptor (XPR1) appears to have
multiple membrane spaning domains and is 696 amino acids in lengt (10, 156, 191).
XPR1 shares homology with the yeast protein SYG I (25% identity, 37% 
similarty) (10
156, 191) The yeast protein SYG 1 appears to playa role in G protein-coupled mitogenic
signaling (145).
Chapter I - TABLE 1. Murine Retroviral Receptors
Virus Receptor gene Function
Ecotropic MuL V
Amphotropic MuL V
Xenotropic MuL V
Polytropic MuL V
Gibbon Ape Leukemia Virus
HIV-
Rec-
Ram-
Xmc-
Rmc-
GLVR-
CD4
CCR5 , CXCR4
cationic AA transporter 
phosphate transporter 
unknown 
unkown 
phosphate transporter 
differentiation antigen 
chemokine receptor , f
a (86)
b (82)
c (10
, 156, 191)
(130)
(46)
(32 , 42)
B. MCF Induced Pathogenesis
The mechanism by which the MCF viruses induce disease is unclear. The viruses
themselves do not contain transduced cellular proto-oncogenes. One theory for the
mechanism of transformation is that the transformed cells are immune system cells and
MCF infection may stimulate the cells with a chronic autocrine signal leading to lymphoma
induction. One example of the mechanism of transformation involves the binding of the env
gene product to a growt factor receptor whose signal induces cell proliferation (94). The
MCF envelope protein, gp70 has been shown to bind to the cellular receptor for
eryhropoietin (Epo-R) (94). When MCF gp70 and Epo-R were co-expressed in an IL-
dependent lymphoid cell line, factor independent proliferation of the cells was observed.
The Epo-R was not used for viral entr into the cell, but may provide a growth advantage
to cells infected with MCF virus. Wang et al. (182) showed that complex formation of
gp52 with Epo-R was not sufficient for either mitogenicity in cell culture or induction of
splenomegaly in mice. Wang et al. further showed through a series of envelope
glycosylation mutants that processed forms of 
env protein were required for pathogenicity
(182). Envelope proteins with two or more glycosylation signals mutated were able to
form complexes with Epo-R but no longer induced splenomegaly (182). One diffculty
with role env protein may play in the mechanism of MCF induced leukemia is that Epo-
is not expressed in T -cells which are the target for MCF induced leukemogenicity (31). In a I i
.' :
series of experiments using an IL- dependent T-cell lymphoma line (4437A) Flubacher et
al. showed the majority (:;90%) of the IL- independent lines established from polytopic
or xenotropic virus-infected 4437 A cells car provirus insertions in the 3' untranslated
region of the IL-9 receptor gene (50). An in vivo series of experiments conducted by AI-
Salameh and Cloyd (3) looked at phophatidylinositol signal transduction in thymocytes
from AK mice infected with oncogenic and non-oncogenic MCF viruses. AI-Salameh and
Cloyd found that only the oncogenic MCF virus induced phosphatidylinositol signal
transduction. They also found that this signal 
transduction was chronic after MCF env
expressIOn.
Another theory for the mechanism of transformation by leukemia viruses is a change
in expression of cellular proto-oncogenes by integration of retroviruses into nearby cellular
DNA (67 , 114). There are at least two different mechanisms that alter gene expression
levels of nearby cellular proto-oncogenes (28 , 30, 67 , 114, 172). The first mechanism is
promoter insertion. Promoter insertion is a frequent occurence in avian leukosis virus
(AL V) induced bursal lymphomas. The AL V genome has been shown to integrate
upstream, downstream, and within the c-myc gene (172). Integrations in the same
transcriptional orientation and alterations in the size of c-myc RNA transcripts characterize
:IQpromoter inserton events. Elevated levels of c-myc containing transcripts often accompany
these alterations. Integrations in the reverse transcriptional orientation with no alteration in
the size of c-myc transcripts accompanied by elevated levels of c-myc transcripts are termed
enhancer activation. The mechanism of enhancer activation is thought to occur by the
enhancer contained within the viral L TR sequence up-regulating gene expression of nearby
proto-oncogenes (185 , 186). Consistent with these observations is the finding that in MCF
247 induced early lymphomas of AK mice 10-20% show MCF 247 viral integration s near I .
\ .
c-myc (97).
C. Enhancers Contained in the LTR I ,I :
I. '
1 .
Studies of recombinant retroviruses generated by combining L TR regions from
MuL V s with different disease properties have mapped a major determinant of disease
specificity to the U3 region of the LTR (19 33- , 71 , 78 , 79 , 96). Although other gene
regions of MuL V s have been implicated as additional determinants for disease specificity,
the strong effect seen with U3 recombinants may mask or obviate the other weaker gene
II'-
determinants (71 , 91 , 132). Within the U3 region are tandem direct repeat sequences that
function as transcriptional enhancers (88 , 89). Specific protein-binding sites within the
enhancers of these MuLVs regulate cell-tye specific transcription (13 , 75 , 99 , 116
146 , 162 , 169).
Spontaneous tumors of AKR mice contain viruses with duplicated enhancer Inl
!III
,jUJ
sequences even though the identified endogenous virus that is the U3 donor for
leukemogenic MCF viruses (BXV- l) contains a single copy of the enhancer (70, 125 , 153).
!\h I
Holland et al compared the oncogenic potential of MCF viruses with one enhancer (MCF
30-2) versus two enhancers (MCF 247) and found the oncogenic phenotye correlated with
'II
i:l
111
ill 'the presence of duplicated enhancer sequences (72). The thymotropic phenotye of both
viruses is independent of the number of copies of the enhancer sequences. The oncogenic
phenotye of MCF 247 is correlated with the presence of duplicated enhancers or the
presence of an enhancer with a specific sequence (72). The previous study suggests the
leukemogenic potential of MCF viruses is dependent upon either the duplication of the U3
enhancer element or a unque sequence generated between the duplicated enhancers. Thee
lines of evidence support this suggestion. First, all spontaneous tumors examined by Stoye
and Coffn contained proviruses with duplicated enhancers (personal communication).
Furhermore, DiFronzo et ai, (39) show that the chimeric virs ofMCF 247W containing
the LTR from MCF 247 1b, a molecular clone ofMCF 247 with a single copy of the
enhancer sequence, and MCF Idr supF
, the supF- tagged version of this chimeric virus, have
a reduced leukemogenic potential in AKRJ mice compared to MCF 247 (chapter IlI-
p".
Figue 1). Finally, duplicated enhancers are required for the oncogenic potential of other C-
type viruses (45 , 166).
At least ten common sites of proviral integration have been implicated in murne
retrovirus-induced T-cell leukemogenesis in either mice or rats (29
, 105 , 139, 167 , 168
177 , 178). C-myc is the most frequently rearranged cellular proto-oncogene in AKR thymic
!/r
;ia
'I 
ill
tumors occurng in 12% to 25% of tumors (1, 28 , 127 , 135 , 193). Other sites of frequent
integration include pim- , pim- pal- , bla- (171), bmi- , emi- , tmi- (66), gf- l (134),
evi- (98), and ets- (12). Proviral integrations have also been observed in genes other than
oncogenes (143). Sorensen et al identified the major histocompatibility complex (MHC)
!! ,
:11 .
class II E- , protein kinase C-
ll, and T-cell receptor -chain genes as sites of integration III
!II
(143). The integrations were not monoclonal in origin and may only playa secondary role
11 .in lymphomagenesis (119 , 143 , 183).
Most ALV-induced B lymphomas have proviral integrations aligned in a manner
compatible with activation of c-myc by promoter insertion (67 , 114). In contrast, in MuL V
induced T cell lymphomas , nearly all provirses located within 2 kb 5' of the first exon of
c-myc are in the opposite transcriptional orientation (28
, 118 , 127 , 135). This suggests
that MuL V induced T lymphomas involve enhancer activation of the cellular proto-
oncogene (33- , 71 , 73 , 78, 79 , 91 , 96). Studies have shown that integration of pro viruses
near cellular proto-oncogenes may result in the deregulation of the normal transcription
level of these proto-oncogenes (28 , 30, 67, 114, 117, 122 , 172).
Viral genetic selection for improved enhancer fuction has been a powerfl tool 
the analysis of the strctue and fuction of the enhancer sequences ofSV40 (89 92).
Specific mutations in the enhancer sequence were shown to debilitate SV 40 enhancer
function. Passage of mutant viral stocks, resulted in viral isolates with improved growth
propert (69). These isolates when characterized revealed important strctural and
functional properties of the enhancer (69).
A similar approach has been used to analyze the structures of the SL3-3 and MCF
13 proviral LTRs (21 , 113). These investigators characterized the LTRs of pro viruses :11..U i
'\1 '
!1J
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integrated near oncogenes in tumors. They used viruses that either contained two enhancers
with point mutations that made them less leukemogenic, or one enhancer with additional
L TR deletions. Chen and Yoshimura analyzed tumors from AKR mice injected with MCF
13 viruses that had a portion of U3 between the enhancer and promoter removed (21). This
region,downstream of enhancer (DEN) was previously shown to play an important role in
transcriptional activation and virallymphomagenicity (75 , 169). They examined tumors
from AK mice injected with MCF 13 viruses containing either one enhancer or two
enhancer elements with the DEN region removed (21). The incidence 
of c-myc
rearangement for the mutant viruses was similar to that of the wild-tye MCF 13.
Eighteen percent (2 of 11) of tumors induced by the virus containing two enhancers showed
c-myc re-arrangements. Fifteen percent (2 of 13) of tumors induced by the virus containing
one enhancer showed c-myc rearangements. Twenty percent of tuors from wild tye
MCF 13 virus showed c-myc rearrangements. The DEN deleted provirus containing two
enhancers isolated from tuors with a rearranged c-myc gene contained the same L TR
strctue as the injected virs, although one tumor acquired a six base pair insertion. The
DEN deleted provirus containig one enhancer isolated from tuors with a rearanged
c-myc gene contained L TRs that had acquired additional enhancer sequences during
lymphomagenesis. The additional sequences could have been acquired from endogenous
xenotropic BXV - 1 provirus or spontaneously generated MCF viruses. It is most likely
however that the additional sequences were generated from the injected virus. This is
because the additional sequences contained the junction sequence generated by the deletion
1)1
1;'1
of the DEN region in the input virus. They also observed the proviruses from the tumors
from the animals injected with the DEN deleted virus with one enhancer were integrated in
the same transcriptional orientation as 
c-myc (21). The proviruses they observed in these
The virally induced leukemogenicity observed when a provirus is integrated in the
tumors all acquired additional enhancer elements.
same transcriptional orientation as 
c-myc may involve a mechanism similar to that seen in
AL V induced lymphomas. In AL V induced lymphomas
, activation of c-myc is induced by
promoter insertion (67, 114). The MCF virus (MCF 13LlEN) with one enhancer used by
I I
Chen and Yoshimura contained additional deletions in U3 that are not found in BXV -
, the
endogenous proviral U3 donor. The additional deletions complicate the analysis of
enhancers that are biologically selected for integration near oncogenes. Chen and Yoshimura
address the issue of whether the region downstream of the enhancer is involved in
leukemogenicity and whether specific point mutations are maintained. They do not
characterize the strcture of the enhancer region that is required in a leukemogenic virus.
My study is unique in that I unambiguously identify the injected 
virs through the use 
the supF tag. I utilized the supF tag to locate injected virses that have integrated proximal
to c-myc. Any changes in the enhancer region of the injected virus integrated near 
c-myc are
identified by PCR cloning and sequencing. The proviral U3 region of the injected virus
contains one enhancer element similar to BXV - 1. If the proviral enhancer region is altered
in vivo I can identify the sequence changes. By sequencing the L TRs from proviruses
found in tumors and identifying the sequence binding sites used by known transcription
factors , possible changes in transcription factor binding sites may be elucidated. Analyzing
,tJ
Ii;!
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these L TRs wil provide clues to the sequences that are important to viral enhancer
function. This approach is based on the assumption that the strctures of the L TRs of
viruses inserted near oncogenes are importnt for oncogenesis and therefore are biologically
selected for necessary enhancer fuction.
il :
This thesis examines two different properties of polytopic murne leukemia
II .
viruses. The first propert examined is the ability of polytopic MuL V s to infect human
cells. The first hypothesis that I tested is that polytopic MuL V s can effciently infect
human cells and be useful tools for human gene therapy. In the second chapter I determined
the infectability of varous human cells and cells lines with polytopic MuL V. I created a
packaging cell line that produces vector virus with a polytopic envelope protein on the
surace. Virus from this cell line was used to determine what populations of cells the vector
can transduce. I then used replication competent virs to identify which cell populations
could support polytopic virus replication and the interference patterns displayed with
each cell tye. The second propert I examined was the proviral enhancer changes that
occur in tumors of AKJ mice induced by a polytopic virus containing one enhancer and a
molecular tag (supF). The hypothesis that I tested is that specific sequence alterations and
enhancer duplications wil be selected in proviral integrations proximal to 
c-myc in tumors
.,'
of AKRJ mice. In the third chapter I examined the sequence changes that occur in the viral
enhancer during in vivo replication and progression to leukemia induced by a polytopic
MuL V containing a single enhancer and a molecular tag. This dissertation studies two
important genetic determinants of pathogenic MCF viruses that are acquired during
recombination. The unique envelope gene generated following recombination allows the
1)11
1:1
1\:1
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virus to utilize a different receptor to infect cells. Unique L TR sequences are acquired
during recombination and usually undergo fuher modifications.
'I 
CHAPTER Il*
GENE TRANSFER TO HUMAN CELLS USING RETROVIRUS VECTORS
PRODUCED BY A NEW POLYTROPIC PACKAGING CELL LINE
I report here the construction of a new packaging cellUne, called MP AC,
derived from a Moloney mink cell focus-inducing (Mo-MCF), polytropic virus. 
':1
1:1
Il,
that packages defective retroviral vectors in viral particles with envelope proteins
characterized the tropism of MP AC-packaged retroviral vectors and show that some
human cellUnes can be infected with these vectors while others cannot. 
addition, I show that some human cells fully support MCF virus replication while
others either partially or fully restrict MCF virus replication.
The utility of retroviral vectors for transferrng genes to cells is determined by the
presence or absence of cell surface receptors for the virus on the target cell and by post
penetration events that affect viral replication. Receptor interference studies show that
ecotropic , amphotropic, xenotropic, and polytropic murne leukemia viruses (MuLVs)
each utilizes distinct cell surace receptors (22 , 25 , 126, 128 , 129, 142). Packaging cell
lines that package defective retroviral vectors into ecotropic (104) and amphotropic (27
107, 108) envelope proteins have been developed and extensively characterized by using
murne leukemia viruses. Although constrction ofxenotropic virus packaging (52) and
Friend polytopic virus packaging (110) cell lines have been reported, they have not been
extensively characterized or utilized in the published literatue.
* Published in J Virol1997 Joo 71:6 4825-
Murne leukemia virus-based packaging cell lines have been used for tracking the
differentiation of hematopoietic lineages (37
, 60, 80 , 90, 123 , 141 , 144), identifying viral
receptors on specific cell tyes (52 , 110, 188), and gene transfer (27 , 104, 107
108 , 131 , 187). To aid in our studies of retroviral pathogenesis by mink cell focus-
inducing (MCF) viruses , I generated a cell line that packages retroviral vectors into MCF
virus envelope proteins and characterized the ability ofMCF virus envelope packaged
retroviral vectors to infect human cells.
In order to generate an MCF virus envelope packaging line
, I constrcted a virus-
derived genome that expresses MCF virus envelope glycoproteins
, produces all the
retroviral proteins necessary for retroviral assembly, and yet is defective in packaging its
own genome. I used the plasmid pPAM3
, constrcted by Miler and Buttimore
, to form
the backbone of the defective viral genome (107)(Figue I). A 6. kb fragment containing
most of the gene of the MCF envelope (including all of gp70-SU and most ofpl5E- TM),
as well as the polymerase gene (pol), a porton of a the capsid gene (P30-CA) and all of the
nucleocapsid gene (PlO-NC) was isolated from pMo-MCFI- 1 (14) and used to replace the
amphotropic envelope gene in pPAM3. The resulting plasmid was named pMPAC. The
integrty of the clone was verified by digestion with 
Hin dIll Eco , and Pst I restrction
enzmes. pMP AC retains the 5' long terminal repeat (L TR), the splice donor site, the
p15-matrx gene, the p12 gene, the 5' portion of the p30-CA gene, the 3' porton of the
envelope p15E-TM gene and the poly(A) addition site from pPAM3. The 3' portion of
p30- , all ofplO- , the polymerase gene, the envelope (gp70) gene, and the 5' portion
of the p15E-TM gene, are derived from pMo-MCFI- as shown in Figue 
Xho I
5' LTA S) AT 
PMPAC gag
!..
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Chapter II - Figure 1. Constrction and characterization of a MCF-virus packaging plasmid
pMP AC. In white are the regions of the genome derived from pP AM3 , including the 5' L TR , the
splice donor (SD), the start site (ATG), a portion of the gag and env genes, the termination site
(TAG), and the simian virus 40 (SV40) poly (A) signal (hatched boxes). The restrction enzme
sites (Xho I and Cia I) shared between pPAM3 and pMo-MCFI- 1 were used to introduce the
envelope gene as well as other sequences derived from pMo-MCF I- I (14). Sequences derived
from pMo-MCF1- 1 are stippled.
pol SV 40 Poly A
(Bell)
env
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To generate the packaging cell line, the defective virs-derived genome of pMP AC
was excised from the plasmid vector and co-transfected (19 g) with pSV2his (I g) into
NIH 3T3 cells. Transfected cells were selected with 5-mM histidinol. After ten days of
selection with histidinol, isolated histidinol-resistant colonies were clearly visible on the
plates. Thirt of these colonies were isolated with cloning cylinders and expanded into
separate cultures.
To identify cell lines producing high titers ofretroviral vectors, a reverse
transcriptase (RT) assay was performed on media (supernatant) collected from confluent
cultures. Three lines (MPAC- , MPAC-95, and MPAC-2433) that produced high
levels ofRT (::1 x 10 cpmlml) were transfected with pLXSH, a retroviral vector
containing a hygromycin resistance (Hygro ) gene (109). T ansfected cells were selected
with hygro (70 g/ml), cloned, and expanded. A viral stock was isolated from each
transfected cell line and titers were determined on NIH 3 T3 cells. One clone of the
packaging line, MP AC- , consistently produced titers of virus higher than those
produced by other lines (0. 5 x I 6 to 1 x 10 Hygror CFU/ml). I separately transfected
other defective retroviral vectors that contained selectable or identifiable markers
including pBAG (containing the beta-galactosidase ( Gal) gene) (124), pDAP (containing
an alkaline phosphatase gene) (47), and pZIP-SV(X)Neo (containing a neomycin )11
:,1
resistance gene, which confers resistace to G418) (17) into our packaging cell lines.
I have grown BAG(MPAC-91) cells in the CellmaxCI arficial capilary cell cultue
:'1
system and generated MP AC-packaged pBAG viral stocks with titers of 5 x 10 CFU/ml.
Therefore, the MP AC cell line functions as a packaging line and can package a variety of
retroviral vectors into retroviral paricles.
To determine if the MPAC cell line produced replication-competent viruses
, two
tests were performed. Two 100-mm-diameter plates of Mv- Lu cells were infected with
virus harested from ZIP(MPAC-91) cells (multiplicity of infection, (MOI) = 1.2). As a
control, two parallel plates were infected with the replication competent virus MCF 247
(3 mVplate). The cells were cultued separately, for 4 weeks at I x 10 to 4 X 10 cells per
dish. Supernatants (l-ml aliquots) were harested from each infection and assayed for RT
activity. RT assays of the ZIP(MPAC-91) infections were consistently negative, while
cultues infected with MCF 247 were consistently positive. In a second test, NIH 3T3
and Mus dunni cells were infected with BAG(MP AC-91) virus (MOI = I). The cells were
cultued for 2 weeks as described above. After cultue, supernatant was harested from
the cultues and used for a RT assay (1-ml) or to infect fresh NIH 3T3 and 
M dunni cells
(3 ml each). Two days after the infection
, the NIH 3T3 and M dunni cells were fixed and
stained for Gal activity. No blue cells were detected, and the RT assays were negative.
These results suggest that the generation of replication-competent virus in the MP AC line
is a relatively rare event.
To determine the tropism of MP AC-91 packaged vectors , the ability of
BAG(MP AC-91) to infect cell lines of different species was compared to that of MCF
~~~
247 , the prototyical MCF virus (65 , 71 , 73) (Table 1). In every cell line tested
, when 
;11
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Gal positive cells were detected after BAG(MP AC-91) infection, R T activity was
detected in parallel cultures infected with MCF 247. Cell lines that became Gal positive
were consistently able to support MCF virus replication and to produce RT activity,
suggesting that the cells could support both MCF virus receptor-mediated infection and
replication of the virus. I conclude that the tropism of BAG(MP AC-91) was identical to
that ofMCF 247 in every cell line tested.
Reports on replication of MCF viruses in human cells are relatively rare.
Fischinger et al (48) reported that HIX, a biological MCF isolates , could infect human
embryonic muscle skin cells. However, the titer of the virus was not reported. Cloyd et al
(25) tested 11 different MCF isolates and reported that nine did not replicate in a human
embryonic lung cell line (IMR-90), and that two replicated 2000 to 5000 times less
effciently than in a min cell line (Mv- Lu). Harley et al (65) tested nine MCF strains
and reported that none infected a human rhabdosarcoma line (RD). Studies by Sommerfelt
and Weiss (142) established that there are seven distinct receptor groups for C-
tye and
tye retroviruses on human cells, but polytopic MCF viruses were not examined.
Cha ter II - TABLE Tro ism of MCF viruses
Cell line Species Cell type RT activity (dpm/ml) Gal activity (CFU/ml)
of cells infected with of cells infected with
MCF 247 BAG MP AC-9l 
NIH 3T3 Mouse fibroblast 2 x 105 1.2 x 105
M. dunni Mouse tail fibroblast 2 x 105 2 x 104
CHO Kl Hamster ovar
Hamster-mouse hybrid ovary epithelial NTd 1.0 x 105
Mv- Mink lung epithelial 1.4 x 105 1.9 x 104
293 Hwnan embryonal kidney 5 x 104 6 x 103
HeLa Hwnan ovary epithelial
Cells were infected with replication-competent MCF 247 then assayed for RT activity after 4 weeks of
cultue. The values are the averages for supernatant from thee separate experiments.
Cells were infected with serial dilutions ofBAG(MPAC-91) supernatant for 24 h. Two days later, the
cells were fixed and stained for Gal activity. Clusters of four or more blue cells were scored as a CFU.
The values are the averages from thee separate experiments.
c Contains a portion of mouse chromosome 1 and the MCF virus receptor gene (87).
, riot tested.
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Therefore, I decided to explore the ability of MCF virus envelope-packaged vectors to
infect human cells, since published reports ofMCF virus infection of human cells needed
to ;be extended and expanded.
I separately infected six additional human cell lines with MCF 247 and a
xenotropic virus, BALB-IU- 1 (64), as well as two mouse and one mink cell lines as
controls. After at least eight passages and 3 to 4 weeks of cultue, supernatants were
collected and RT levels were measured (Figue 2). Three human cell lines (293 , MCF7
and 2780) supported both MCF 247 and BALB-IU- l replication, as indicated by a RT
value at least fivefold over background. Using the same criterion, four human cell lines
(SW620 , U-373 MG, HepG2 , and HeLa) supported BALB-IU- 1 replication but restrcted
the replication MCF 247. The human cell line 769-P restricted replication of both MCF
247 and BALB-IU- l. These data were confirmed and extended by infecting cultures of the
same cell lines with BAG(MP AC-91) and, 48 h later, staining to detect the expression of
Gal (Figure 3). HeLa and CHO-Kl cells as well as uninfected cells of each tye were
included as negative controls. The results of this experiment confirm the results with
'1\0
LJI
Ljl
replication-competent MCF 247 and suggest that the restrction in replication of MCF
247 in some cells lines (e. , SW620) is more apparent with replication-competent virus
than with the defective vector. One explanation for this could be differential transcription
of the vector and the virus in infected cells. This is possible, since the L TR and other
control elements ofMCF 247 and pBAG, the defective vector used in these experiments
differ.
To confirm that the cell lines that clearly support MCF virus replication (293 and
MCF7) were human, these lines were reacted with an anti-human fluorescein
isothiocyanate (FITC)-labeled monoclonal antibody against HLA class I antigens (clone
W6/32; Sigma) and examined with a confocal microscope as described previously (2).
When 100 cells from each line were examined, both human cell lines reacted positively
with the monoclonal antibody, whereas mouse NIH 3T3 cells did not (data not shown). In
addition, both 293 and MCF7 cells were obtained from American Type Cultue Collection
and the experiment was repeated qu titatively with a Zeiss fluorescent microscope
(FITC positive cells/total cells scored; for NIH 3T3 , 0/220; for 293 298/299; for MCF7
542/555). Therefore, more than 99% of the cells of each cell line were identified as human
by virte of their reaction with the antibody.
'0 
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Chapter II - Figure 2. The RT activity of media collected from infected cells 4 weeks
after infection with MCF 247 or BALB-IU- l was determined in duplicate as previously
described (6 9). The total number of disintegrations per minute per mililiter of
supernatant minus the background is plotted. To determine the background, one aliquot
of the RT assay mix was spotted onto fiters, dried, washed three times in 5%
trchloroacetic acid, dred with 95% ethanol, and counted with scintilation fluid on a
Beckman scintilation counter. This background ranged from 0.9 x 10 to 1.0 X 10 dpm
depending on the experiment, and was subtracted from all samples. In addition, the
background for each unfected cell line was determined by assaying 1 ml of supernatant
from uninfected cells for RT activity. This background ranged from 1.4 x 10 to 4.4 X 10
dpm, depending on the cell line and the experiment.
;jj
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Cell Lines
Chapter II - Figure 3. The titer of BAG(MP AC-91) was determined by separately
infecting the indicated cell lines with lO-fold serial dilutions ofBAG(MPAC-91).
Infections were performed as described previously (6). After 48 h, cells were fixed with
2% paraformaldehyde-2% gluteraldehyde in phosphate-buffered saline and stained for
Gal activity for 24 h with a solution containing I mg of X gal (5-bromo-4-chloro- indolyl-
galactopyranoside) per ml, 5 mM potassium ferrc cyanide, 5 mM potassium ferrous
cyanide, and 2 mM magnesium chloride in phosphate buffered saline. Monolayers were
scored microscopically (with a Zeiss Axiovert microscope) as positive when the
cytoplasm of the cell was uniformly blue. Uninfected cells of the same 
tye were stained
and used as negative controls. BAG(MPAC-91)-infected NIH 3T3 cells were used as a
positive control.
The 293 and MCF7 cell lines from the American Type Culture Collection were
also infected with BAG(MPAC-91) virus or replication-competent MCF 247. The
results of that experiment were similar to those shown in Figures 2 and 3. The percentages
of both 293 and MCF7 cells that had Gal activity exceeded the percentage of cells that
were FITC negative in the previous experiment. This demonstrates the documented
infection of the human cell lines did not result from contamination of the human cells with
a minor population of murne cells. I conclude that 293 and MCF7 are human cell lines
that support infection by BAG(MPAC-91) and replication of MCF 247.
To determine if these results could be extended to primar human cells , four
primary cell cultues (human foreskin fibroblasts (HFFJ, monocytes, renal epithelial cells
and renal mesangial cells) were infected with BAG(MPAC-91) vector at an MOI of 1.
Two days later, the cells were fixed and stained for Gal activity. None of the four
primary cell cultues examined stained positively for Gal activity. Although the cells
exhibited a normal morphology and were readily infectable with other virses (e. , HFF
supported cytomegalovirus infection and monocytes and renal cells supported human
immunodeficiency virus infection (data not shown)), they did not stain positively for.
Gal activity. These data show that the primary cells did not support BAG(MPAC-91)
infection (Table 2).
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Chapter Il - TABLE 2. Characterization of the ability of cell lines to support
MCF virus replication
Primary Cells Established cell line (description)MCF virus
replication support
Fully Supportivea
Restricted
N onsupporti ve
293
MCF7
2780
SW620
373 MG
HepG2
769-
HFF
Monocyte
Renal epithelial
Renal mesangial
C8166
CEM
G401
HeLa
HL-
562
Mes-
Raji
T84
937
(primary embryonal kidney)
(breast adenocarcinoma)
(ovaran carcinoma)
(colon adenocarcinoma)
(glioblastoma, astrocytoIla)
(hepatocellular carcinoma)
(renal cell adenocarcinoma)
(T cell)
(T lymphoblastoid)
(Wilms ' tumor)
(T -cell lymphoma )
(epitheloid cervical carcinoma)
(promyelocytic leukemia)
(chronic myelogenous leukemia)
(muscle sarcoma)
(Burkitt lymphoma)
(colon carcinoma)
(histiocytic lymphoma)
Defmed as having RT values of more than fivefold over background and a
BAG(MPAC-91) titer of). 100 CFU/ml.
Defined as having RT values between background and fivefold over background and
a BAG(MP AC-91) titer between I and 100 CFU/ml.
C Defmed as having R T values equal to background or a BAG(MP AC-91) titer of -( I
CFU/ml.
However, I cannot rule out the possibility that other human primary cells , under certain
conditions , might be able to support BAG(MP AC-91) infection.
I also characterized the interference properties ofBALB-IU- l and MCF 247 in
two of the human lines capable of supporting replication of both viruses and
, in addition
in a mouse cell line M dunni and a mink cell line, Mv- Lu. Previous interference data
showed that xenotropic and MCF viruses form separate interference groups in inbred
mouse cell lines (e. , NIH 3T3) whereas xenotropic and MCF viruses form one
interference group in wild mouse lines and in some cell lines of other species (48
, 65 , 128).
Additional data suggest that interference groups may vary when the same viruses are
tested in different cell tyes (22). I measured the titer ofBAG(MPAC-91) on xenotropic
virs-infected and uninfected 293 , MCF7 M dunni and Mv- Lu cells (Table 3). In each
case, infection with BALB-IU- l interfered with infection by BAG(MPAC-91), suggesting
that polytopic and xenotropic viruses use the same receptor on the surface of these cells.
In conclusion, I have generated a packaging cell line capable of packaging defective
retroviral vectors in a polytopic MCF virus envelope. I demonstrate that vectors
packaged in the line have the same tropism as MCF 247 and can efficiently infect several
human cell lines in vitro. In addition, polytopic and xenotropic viruses form a single
interference group in the human cell lines 293 and MCF7 , suggesting that both viruses use
a single receptor on these cells. These conclusions suggest that the MP AC-91 cell line wil
be useful in studies of the biology, entr and pathogenesis ofMCF viruses.
Chapter Il - TABLE 3. MCF 247 or BALB-IU- l infection interferes with
BAG(MPAC-91) infection
Titera of BAG(MP AC-91) in cells treated
with:Target
cell line
Species
No virus MCF 247 BALB-IU-
M. dunni mouse 2 x 104
Mv- min 1.9 x 104 6:J1.2
293 human 7 x 103
MCF7 human 0 x 102
Expressed as B-Gal-positive CFU per mililiter (MOI = 1). Cells were either
mock infected or chronically infected with the indicated virus 4 weeks earlier. Results are
averages of the values obtained for three identical wells from a single experiment.
DISCUSSION
Constrction of the MCF packaging cell line helped us to identify several key
features of MCF viruses. After accurately determining the tropism for the MCF
packaged viral vectors, I was able to infect several human cell lines. Several groups
previously tested the ability ofMCF viruses to infect a small number of human cell lines
and reported very limited if any ability to infect those cells (25
, 48 , 65). I was able to
show that I could readily infect 293 cells and to a lesser degree MCF7
, 2780 and SW 620
cells. I also demonstrated the ability of293 cells to support MCF virus replication by
the reverse transcriptase assay.
MCF and xenotropic viruses are commonly thought to utilize different receptors
for infection of inbred strains of mice. Previous investigators have noted unique
interference patterns when examining the ability of MCF and xenotropic viruses to infect
wild mice cell lines and some cell lines of other species (22 , 48 , 65 , 128). I showed that in
293 and MCF7 cells , MCF and xenotropic viruses interfere with superinfection of the
other virus group. This data suggests that a single receptor is used by both virus groups
to infect the cells.
It is important to note that although none of the primary and few of the
- Iii
immortalized cell lines tested were effciently infected, some were infected. It will require
fuer testing of a broad range primary and immortalized cell lines to firmly establish the
utility of MCF viruses as a tool for gene transfer and genetic therapy. More importantly,
the utility of xenotropic packaged vectors must be fuher explored in detail. All but one
of the human cell lines was able to support infection and replication of xenotropic virus.
This virus group may provide a useful alternative to amphotropic packaged vectors in
gene transfer and genetic therapies of the futue.
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CHAPTER III
IDENTIFICA TION OF TWO UNIQUE FAMILIES OF ENHANCERS INTEGRA TED
PROXIMAL TO MYC IN SUPF TAGGED POLYTROPIC RETROVIRALL Y
INDUCED TUMORS OF AKRJ MICE
A replication competent MCF virus containing a single enhancer element
and a bacterial amber suppressor tRNA gene (supF) was used to investigate the
alterations that occur in vivo during leukemogenesis. Nine proviral L TRs
integrated near c-myc from four animals were PCR amplified, sequenced
, and or
cloned. All of the enhancers analyzed were from proviruses integrated in a reverse
orientation with respect to c-myc gene expression. I chose to examine proviruses
integrated near c-myc because of their potential biological importance to the
leukemogenic process. One tumor contained a proviral enhancer with only 5 bp
changes relative to the injected virus. The other three tumors contained proviral
enhancers with duplicated enhancer sequences. One integration site encompassing
a duplicated enhancer region and 139 bp of the 
c-myc gene locus was PCR amplified
cloned and sequenced. A search of the current transcription factor databases showed
no known transcription factor binding site sequences were created at the junction of
the enhancer duplications. The common motif of GRE, NF-l, L Vb and core
transcription factor binding sites was conserved throughout the isolated enhancers.
Most of the enhancer elements contained additional NF-KB and/or GRE sites in
close proximity to the conserved L Vb-core region. These results support the
hypothesis that additional NF-KB and/or GRE binding sites cooperatively interact
with the conserved GRE-NF - L Vb-core motif in c-myc induced leukemogenesis. In
addition, two unique familes of enhancers were identifed. The two familes
contained enhancers isolated from different tumors that displayed sequence
homology and transcription factor binding site organization unique to each group.
AKR mice are an inbred strain of mice that develop spontaneous T 
-cell lymphomas
from 6 to 12 months of age (185). Genetic studies have shown thatthe induction of disease
is linked to the inheritance of at least one endogenous ecotropic provirus (e. , Ak) (48
100, 101 , 133 , 153). The causative agent of disease is a virus formed by the recombination
of an endogenous ecotropic virs with other non-ecotropic endogenous retroviral sequences
(48 , 101). Some of these recombinant viruses can infect mink cells and cause cytopathic
foci upon infection. The recombinant viruses are named min cell focus inducing viruses
(MCF) (65). At least two recombinational events occur to form MCF viruses. One
recombination occurs in the 5' portion of the envelope gene to produce a distinctive
envelope glycoprotein (gp70). This unique envelope glycoprotein allows the virus to use
the polytopic receptor instead of the ecotropic receptor to infect cells. When compared to
endogenous ecotropic virses, MCF viruses have a broader host range of species they can
infect (74, 160). A second recombination occurs in the 3' portion of env and incorporates
unique L TR sequences that are important determinants of leukemogenicity. Most MCF
viruses with one direct repeat enhancer element are weakly pathogenic (72 , 73). Whereas
most MCF viruses containing two direct repeat enhancer elements are strongly pathogenic
(72, 73). Twelve to twenty-five percent ofMCF induced early lymphomas of AK mice
show MCF viral integration s near c-myc in an opposite transcriptional orientation (1
, 28
118).
Studies of recombinant retroviruses generated by combining L TR regions from
murine leukemia viruses (MuL V) with different disease properties have mapped a major
determinant of disease specificity to the U3 region of the L TR (19
, 33- , 71 , 78 , 79 , 96). - t
Within the U3 region are tandem direct repeat sequences that function as transcriptional
enhancers (88 , 89). Specific protein-binding sites within the enhancers of these MuL V s
regulate cell-tye specific transcription (13 , 21 , 75 , 99, 116, 146, 162 , 169). Golemis et al
identified regions of conservation in the U3 sequences of 35 
tye C mammalian retroviruses
(57). They aligned the U3 region of sequences that correspond to binding sites for leukemia
virus factor b (L Vb), a viral core-like element (core), the consensus motif for nuclear factor
. .
(N I), and the glucocortcoid response element (GRE) (57). This region of transcription
factor binding sites is thought to provide a framework for "enhanceosome" formation (39
, 147). The enhanceosome is a nucleoprotein complex formed by the assembly of short
regions of DNA (-100 bp or less) containing transcription factor recognition sites with
specific transcription factors (11 , 16 , 158). The enhanceosome is a specific
organization of protein-protein, protein-DNA interactions that fuction cooperatively and
synergistically to assemble the "transcriptosome" machinery and activate transcription (II
, 158).
Investigators have identified other transcription factor binding
- sites within the
enhancer region that is critical for pathogenesis (5
, 62, 113, 115 , 161 , 169). Thornell et al
identified a specific protein-binding site in the enhancer region of the MuL V SL3-
important for transcription in vitro and in vivo (161). They identified the factor that binds
the site, SL3-3 enhancer factor 1 (SEF- l) (161 162). They showed that mutations within
this sequence reduced the transcriptional activity from U3. They also showed through
DNase I footprinting and gel shift assays the amount of transcription factors binding to the
SEF- 1 specific site were much greater in T-cells than B-cells or non- lymphoid organs.
Hollon et al and Tupper et al identified a protein-binding site in the MCF 13 L TR, which
they termed MLPal (75 , 169 , 192). This site is located in a region of the LTR which they
termed DEN (downstream of enhancer). DNase I footprinting and gel shift assays
identified the binding site, MLPai. Yoshimura et al subsequently showed the presence of
the binding site in conjunction with enhancer sequences could augment transcription in T-
cells (192).
MCF viruses are present and routinely can be isolated from spontaneous tumors of
AKR mice (24, 73). Spontaneous tumors of AKR mice contain viruses with duplicated
enhancer sequences even though the identified endogenous virus that is the U3 donor for
leukemogenic MCF viruses (BXV- l) contains a single copy of the enhancer (70, 125 , 153).
Holland et al compared the oncogenic potential of MCF viruses with one enhancer versus
two enhancers and found that the oncogenic phenotye correlated with the presence of
duplicated enhancer sequences (72). They found that MCF 30-2 and MCF 247 differ in
the number of enhancers in the L TRs. The thymotropic phenotye of both viruses is
independent of the number of copies of the enhancer sequences. Their study suggests that
the leukemogenic potential of MCF viruses is dependent upon either the duplication of the
U3 enhancer element or a unique sequence generated between the duplicated enhancers.
Finally, duplicated enhancers are required for the oncogenic potential of other C-type
viruses (45 , 166). Our lab has extended this observation and demonstrated that disruption
of the integrity of the duplicated enhancer sequence reduces the leukemogenic potential of
MCF 247 (39).
The objective of this study was to look for alterations in the enhancer elements of
proviruses integrated proximal to c-myc. My analysis was limited to L TRs integrated
upstream of c-myc exon 1. This region of the c-myc locus is frequently disrupted in MuL V
induced leukemogenesis and considered to be a critical step in disease-induction (1,
113 , 118 , 127 , 135). Newborn AKR mice were injected with a MCF virus (MCF Idr supF
Figue 2A) with one enhancer whose genome was tagged with the bacterial amber
suppressor tRNA gene supF (Figue 2A). Tumor DNAs were examined by Southern blot
and PCR to identify supF positive tumor DNAs that contained rearanged 
c-myc genes.
The enhancer regions from proviral integrations upstream of 
c-myc were PCR amplified and
sequenced. The varous sequence alterations and duplications in the enhancer region of the
provirus are the subject of this report.
MATERIS AN METHODS
Mice. Newborn AKRJ mice were injected, intrathymically and intraperitoneally
with 100 Jll of undiluted tissue cultue-grown virus stock. Mice were monitored daily for
evidence of leukemia (scruffy fu, labored breathing, lymph node enlargement) and
euthanized when morbid.
Viruses. An infectious molecular clone of MCF 1 dr supF was constrcted by
replacing the LTR from pMCF247-W with the LTR containing one enhancer element from
pMCF247- lb (72). The resulting plasmid was cut at the Pst I site upstream of the
enhancer sequences and blunt ended with T4 DNA polymerase. A Fnu DIl fragment
containing the supF gene isolated from plasmid piAN7 was ligated into the L TR to generate
the supF tagged viral genome (38). To generate virus stocks, the clones were transfected
(20) separately into Mus dunni cells. Transfected cells were passaged for approximately
two weeks to allow the virus to infect every celL Twenty-four to thirt-six hour cultue
supernatants were collected and filtered through 0.45 J.m filters. The titers of the virus
stocks used for injections were determined by using an assay for reverse transcriptase (9).
Southern blots. Southern blotting was performed according to standard protocols
(103). Briefly, genomic DNA from tumors was digested with Asp 718 Eco , or Xba 
Approximately 10 /lg of DNA was electrophoresed on 1 % agarose gels in 1 x Tris-acetate-
EDTA (TAE) buffer and transferred with 0.4 M NaOH by upward capillar wicking to 
nylon membrane. The c-myc probe used was a 2. kbp Sac I-Bam HI fragment ofpB5'
myc (43). The fragment contains 143 bp of exon 1 and approximately 2.0 kbp of upstream
sequence. The supF probe used was a 112 bp Ava I fragment of piAN7.
PCR Amplifcation of proviral L TRs. PCRs were performed with varous cellular
genomic DNA as templates. To determine which of the tumor DNA contained a supF-
tagged provirus an envelope primer (TM
, 5' AAGAGGGAGGTTTGTGTGCT- ) was
used in conjunction with a primer (supF GAAGTCGATGACGGCAGATT- ) in the
supF sequence. To amplify proviruses integrated 
upstream to c-myc an env 
AAGAGGGAGGTTTGTGTGCT- ) or LTR primer (3
AGACCACGATTCGGATGCAAC- ) was used in conjunction with various c-myc
primers (A, 5' TACTACGCTGTGCATTCTGTACAATCCC- ; B
AGT AAAGTGGCGGCGGGTGCGCTCT ACC- ; C
AGTAATAAAAGGGGAAGGCTTGGGTTTG- ; and D
TCCCTCTGTCTCTCGCTGGAATTACTACAG-
) (113). The four c-myc primers
were located at positions 122 to 95 , 627 to 600 , 269 to 296 and 1688 to 1659 relative to an
Xba I site located 1.5 kbp 5' of exon I (28). To amplify the enhancer region the primer pair
(614, 5' CGACTCAGTCTATCGGAGGAC- ) and (S
GCAAGGCA TGAAAGT ACCA- ) was used. Three additional sequencing primers
were used 5' ACCATCTGTTCTTGGCCCTG-
CTGGCCTGCTCCCTT ATCGGG-
GAACTGTGTTCTTGCCCTGCGTATATC- PCR amplifications were performed
in 100 Jll with 10 ro Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgClz, 0. ro each
deoxynucleoside trphosphate, 0.25 ro each primer, 1 U of AmpliTaq Gold polymerase
(Perkin-Elmer Cetus) and 100 ng genomic DNA per reaction. Reaction conditions were
C for 10 minutes followed by 40 cycles of 1 min at 95 , 1 min at 58 , 2 min at 72
then a fmallO min extension at 72 C. Pfu DNA polymerase (Stratagene) was used to
amplify the proviral integration site in tumor # 92106. The amplification primers used
were LTR (5' AGACCACGATTCGGATGCAAC- ) and TEF 85
(5' GAACTGTGTTCTTGCCCTGCGTATATC- ). Amplifications were performed in
100 Jll with 10 ro KCl, 10 ro (NlLhS04, 20 ro Tris-Cl (pH 8.75), 2 ro MgS04,
1 % Triton X- I 00 , 100 Ilg/ml BSA, 0.2 mM each deoxynucleoside trphosphate
, 0. 25 mM
each primer, 1 U of Pfu DNA polymerase (Stratagene) and 100 ng genomic DNA per
reaction.
Cloning of proviral enhancer elements. Proviral L TRs integrated upstream of the c-
myc locus were analyzed using the scheme illustrated in Figure 4. In the first step, primers that
hybridize to the first exon ofc-myc (Myc) and the proviral LTR (T or 3) were used to amplify
tumor DNAs with (a- P)dCTP in the reaction mixture. Primer pairs were selected to detect
proviruses integrated upstream of c-myc in the same (T and Myc) or the opposite (3 and Myc)
transcriptional orientation. In step 2, amplification products were separated by electrophoresis
through a polyacrylamide gel and identified following dring of the gel. In step 3 , radiolabeled
PCR products were excised from the dred gel following alignent of the developed
autoradiograph with the polyacrylamide gel. In step 4
, DNAs purfied from the rehydrated gel
slices were used as templates to PCR amplify the enhancer region with the primer pair Sand 614.
The amplification products were then gel purfied
, re-amplified with primer pair Sand 614, and
either sequenced directly or cloned and then sequenced.
DNA sequencing. Qiagen miniprep or maxiprep DNAs were sequenced using a
Robocycler thermocycler (Stratagene) with an ABI PRISM Dye Terminator sequencing kit
(Perki-Elmer) on an ABI 373 Sequencing apparatus. Each sequence was analyzed using
the computer programs Sequencher (Gene Codes Corporation) and SeqPup (D.G. Gilbert).
Sequences were compared to published sequences contained in the GenBank and EMBL
databases using the BLAST network service (4).
RESULTS
Identification of tagged proviruses integrated near 
c-myc. Virus particles
produced by transfection of the pMCF Idr supF (Figue 2A) DNA into Mus dunni cells
was injected into newborn AKR mice. The virus genome contains a bacterial amber
suppressor tRNA gene supF ligated into the 5' portion of U3 in the L TR. The supF gene
serves as a marker to identify the injected virus from endogenous viruses. Morbid mice
displaying signs ofleukemia (ruffed fu and labored breathing) were sacrificed and DNA
was purfied from their thymic lymphomas (Figue 1). Tumor DNAs from 31 mice injected
with MCF Idr supF viruses were tested for the presence of a supF-tagged provirus using
the supF- TM primer pair and PCR (Figue 2A). Amplification products were
electrophoresed, transferred by Southern blot and hybridized with a 
supF probe. DNAs
from twenty-eight tuors were supF positive (Figue 2B).
AKJ mice rarely develop spontaneous tumors by six months of age
, but the
incidence increases dramatically after that time (39, 133). Newborn mice injected with
MCF 247 wil rapidly develop leukemia with a 100% incidence by 180 days (39
, 133).
Foureen mice developed tumors in less than one hundred and eighty days and wil be
referred to as early tumors. Thirteen of the fourteen early tumors tested positive for the
presence of supF tagged provirs by Southern blot of a supF- TM PCR (Figue 2B).
Acceleration of Leukemia in Mice Injected with MCF Viruses
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Chapter III - Figue 1. Newborn AKR/J mice were inoculated with MCF 247
(2dr) or MCF Idr supFviruses by intraperitoneal (IP) and intra thymic (IT)
injection. Mice were observed for leukemia and the disease incidence is plottec
The number in parentheses is the number of mice in each experimental group.
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Chapter III - Figue 2. Strctue of the MCF ldr)supF virs genome and the presence
of the genome in tuors. (A) The supF gene fragment was inserted in the 5' end of U3
as shown. Arows indicate the positions of the PCR priers used to ampli env-
U3-supF junction fragment. (B) PCR ampliication using the priers indicated by
arrows. Tumor DNAs were amplifed, electorphoresed, blotted and hybridized with a32.P-Iabeled supF probe. 560 bp env-supF PCR product indicated with small arrow.
Seventeen tumors arose more than one hundred and eighty days post-injection and wil be
referred to as late tumors. DNA from fifteen of the seventeen late tumors tested positive
for supF by PCR and Southern blot analysis. Three out of thirt-three tumors did not
contain supF by PCR and the mice likely developed tumors by spontaneously generated
MCF viruses. Only one of the three tumors that did not contain supF was an early tumor.
This percentage is consistent with the percentage of spontaneous leukemia seen in AKRJ
mice in 0:180 days (38 , 133). These results indicate that the tagged virus was
successfully injected into the newborn mice and infected the thymus tissue. These results
also show the supF tag was relatively stable within the virus.
To identify tumor DNAs containing rearangements of the c-myc locus, genomic
DNAs were digested with restrction enzes (Xba Asp 718 , or Eco RI), electrophoresed
in a 1% agarose gel
, transferred to membrane by Southern blotting, hybridized with a c-myc
specific 32P- labeled probe, and autoradiographed. Figue 3 shows a representative Southern
blot containing normal thymus (Thy) DNA and two tumor DNAs (175 and 143). DNA
fragments of 20 kbp, 10 kbp, and 4 kbp are generated from the 
unearanged c-myc locus
digested with Eco Asp 718 andXba I respectively. Tumor DNA 143 shows DNA
fragments of aberrant size indicative of c-myc gene rearangements (lanes 3 , 6, 9), while
tumor DNA 175 does not contain c-myc rearrangements. In total, six of the 31 tuor
DNAs contained rearanged c-myc loci (Table I). Four ofthe six tumors appeared early
(0:180 days), while two tumors appeared after the pre- leukemogenic period ( 180 days).
EcoRI Asp718
M :;
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Chapter III - Figure 3. Southern blot analysis demonstratig a normal
and rearranged c-myc locus. Ten /-g of genomic DNA from normal
thymus or tumors from mice injected with MCF 2dr (Not 9) virus (30)
was digested with the restriction enzymes
, electrophoresed, blotted and
hybridized with a c-myc probe fragment. Thy = normal thymus DNA
175 = tumor DNA with unrearranged c-myc gene, 143 = tumor DNA
with rearranged c-myc gene. 
Chapter III - TABLE 1. Summary of PCR and Southern blot data
Tumors No. of diseased SupF positive Rearanged c-myc Mean latencymice/no. injected" locus period (days 
Early tumors :S 180 days 16/33 13/14 4/13 137:! 7.
Late tuors )0 180 days 17/33 15/17 2/15 221.5:! 8.
" The number of mice with disease is compared with the total number of mice injected with MCF (I dr) supF
virus. Genomic DNA from two tumors was unusable for further analysis.
The number of supF positive tumor DNAs by southern blot of Figure 2 is compared with the number of
usable DNAs from each group.C The number tumor 
DNAs that contain a rearranged c-myc locus is compared with the number of supF
;ositive tumor DNAs from each group.
The mean latency period calculated is expressed as the mean of all mice observed with advanced disease
from each group:l the standard error.
The difference in results of these two groups is not statistically different (unpaired t-test),
but the sample size is small. The percentage of tumors from mice injected with MCF Idr
supF that contained a c- myc rearangement (19%) is consistent with the results previously
observed by other investigators for MCF induced c-myc gene rearangements (28 , 97, 118
135). The data shows little difference in the mean latent period to disease between animals
with tuors that had rearged versus unearranged c-myc genes in either early or late
tuors (137.0:! 7.2 days, early, rearanged; 143.3:! 6.3 days, early, unearranged; 221.5:!
5 days, late, rearanged; 245.5 :! 12.3 days , late, unearanged). Statistical analysis using
an unpaired (two-tailed) t-test showed the varances between either early (rearranged vs.
unearanged) or late (rearged vs. unearanged) tumors were not significantly different.
1/.
Although a trend in c-myc gene rearrangements directly accelerating leukemogenesis can be
inferred from these data it cannot be proven with our populations sample size.
Identification of proviral enhancer elements near 
-myc in tumor DNAs
containing a rearranged c-myc locus. Figure 4 illustrates the analysis of the U3 regions
from supF- tagged proviral L TRs inserted into the c-myc locus. To determine whether the
amplified proviral U3 regions were tagged with 
supF as well as to determine the orientation
of those proviruses , the amplification products were analyzed by southern blot (Figure 5A)
and hybridized with a radio labeled supF specific gene fragment (Figue 5B). In this analysis
the c-myc specific primers A, B , C, or D (113) were used in amplification reactions in
combination with primer T or the LTR primer 3 (see Figue 5A). The four early tumors
that contained a rearanged c-myc locus (92 , 95 , 98 , and 106) were chosen for further
analysis. The two late tumors that contained a rearranged c-myc locus (86 and 90) were not
further analyzed. All four early tumor DNAs contained amplification products that
hybridized with the supF probe (Figue 5B). Only PCR reactions with primer 3 contained
amplification products that hybridized to the 
supF probe, indicating that supF-tagged
proviruses were integrated upstream of c-myc and in a reverse transcriptional orientation.
Step 1. PCR tumor DNAs from MCF (ldr) supF- injected mice
with primers in the L TR and the c-myc locus
Same transcriptional orientation- Primer pair: T and Myc
ol env
supF (177 nt)
Reverse transcriptional orientation- Primer pair: 3 and Myc
primer
aua
32P-labe1ed PCR amplification of virus-myc specifc products
Step 2. Polyacrylamide gel electrophoresis
Step 3. Isolate 32P-labe1ed PCR products of virus-myc specifc
amplifcation products
Step 4. PCR ampli enhancer region with prier pair: S and 614
Clone and sequence enhancer region
Chapter III-Figure 4. Analysis of U3 regions from supF-tagged proviral LTRs
inserted into the c-myc locus.
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Chapter III-Figure 5. Southern blot of PCR products probed with supF. (A)
Locations of priers used in amplification reactions. (B) DNA from tuors 92
95, 98 and 106 as well as from normal thymus from an 8 wk old AKR/J mouse
were analysed using the primer pairs indicated above each lane.
In order to better identify and isolate the amplification products seen in figure 5B
, PCRs
were performed with 32P- Iabeled dCTP (as described in materials and methods).
Radiolabeled amplification products were isolated and named with the tumor number
hyphen, then a product number (e.g. 92- 1) (Figure 6B). The open brackets (Figure 6B)
indicate the amplification products that were successfully isolated. The boxes indicate
amplification products that could not be reamplified (Figure 6B). 32P-labeled amplification
products generated using the primer pairs described above were electrophoresed in PAGE
dred, and autoradiographed. The autoradiograph was aligned to the gel and uniquely sized
DNA fragments that corresponded to a specific product or size range of products was
isolated (Figue 6B). The isolated products were eluted from the gel, resuspended in Tris-
EDT A, and aliquots were used in amplification reactions to amplify the enhancer region
contained in the L TR. Lower molecular weight bands (':650 bp) were not isolated because
they were non-specific products that were also found in the uninfected normal thymus
control (Figue 6B). The amplified enhancers were then either sequenced directly or cloned
and then sequenced (data not shown). There are limitations of this cloning approach. If a
small amount of non-supF containing DNA is amplified in the first PCR reaction it may
serve as a template for the secondar amplification resulting in arifact products being
isolated. The only accurate means of isolating proviral 
enhancers integrated near c-myc is to
isolate the junction fragments containing the enhancer and upstream 
c-myc DNA sequence.
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Chapter III-Figure 6. Identification of proviruses integrated upstream of c-myc
using a PCR-based approach. (A) Locations of primers used in amplifcation
reactions. (B) Autoradiograph of radiolabeled PCR products electrophoresed
on an acry1amide gel. The lanes are identified by the primer pair used in each
ampliction reaction and the tumor DNA used as the template. Open brackets
indicate products that were reamplified and either sequenced directly or cloned
and then sequenced. Closed boxes indicate products that did not reamplif with
supF-LTR primer pair. Underlied products were sequenced directly.
Analysis of cloned enhancer elements. Nine different enhancer sequences were
isolated with six sequences being unique. A Blast search of GenBank with the six unique
sequences produced significant homologies to four other murine leukemia virus enhancers
(MCF 30- , MCF 247W, MCF- Tikaut and MCF 1233). A clustal alignment was
performed on the nine sequenced products along with the four homologous murine leukemia
virus enhancers (data not shown). The nine sequenced products were segregated into three
different groups based on their sequence homologies (Figures 7 , and 10). Group I is
homologous to the injected virus with few base changes and no signficant enhancer
duplications. This group contains products (95-4 and 98- 1) from tumors 95 and 98. Both
products contained one enhancer along with several differences upstream of the enhancer.
The two products were nearly identical to the injected virus with few base changes except
for a conserved G-A point mutation that maintains an NF-Kb site but may disrupt or create
an unown transcription factor binding site (Figue 8 , and Table 2).
Group II is homologous to the injected virus but contains duplicated enhancer
regions. This group contains products (92- , 95- 1 and 95-2) from tumors 92 and 95. Two
different size enhancer duplications were seen (Figue 7 and 9). One enhancer contained a
134 bp duplication (92- 1) and two enhancers had 84 bp duplications (95- 1 and 95-2). In
addition, although two of the thee cloned enhancer elements had different size duplications
the sequences themselves were quite homologous to each other. The duplicated sequences
in these enhancers encompassed binding sites for C/EBPbeta
, LVb, Core, E-Box and
GRE/E47 (Figue 7).
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Chapter III-Figure 8. Sequence alignent of enhancer group 1 and MCF(ldr)supF. The sequence
of the trancription factor binding sites is underlied with the factor listed above. The supF
inerton site is indicated in brackets.
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GCTCGCTTCTCGCTTCTGT AACCGCGCTTT
9CTCGCTTCTCGCTTCTGT AACCGCGC
CTCGCTTCTCGCTTCTGT AACCGCGCTTT355 365
MCF(ldr)supF ATaCT(::cccAGCcb AT AAA
92- A TGCTCCCCAGCCCT AT AAA
95-
95-
MCF-Tikaut TTGCTCCCCAGCCCT AT AAA
Chapter III-Figue 9. Sequence alignent of enhancer group 2 and MCF(ldr)supF and MCF-
Tikaut. The sequence of the transcription factor binding sites is underlied with the factor
listed above. The supF inserton site is indicated in brackets.
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MCF(1dr)supF TGAAAGACCCCACCATAAGGCTT AGCAAGCTA TGCA AACGCCATTTTGCAAGGCATGAAAAAGTACCAG.
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106- AACAAGAACAAGGAAGTACAGAGAGGCTGGAAAGT ACCGGGACTAGGGCCAAACAGGA TA TCTGTGGTCAMCFI233 TGAAAGACCCCACCA T AAGGCTT AGCC AGCT AACTGCAGT AACGCC AT CTTGC AAGGCA TGGGAAAA T ACC AG 1.1.
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Chapter II-Figure 10. Sequence alignent of enhancer group 3 and MCF(ldr)supF and MCF 1233.
The sequence of the trancription factor binding sites is underlined with the factor listed above. The supF
inerton site is indicated in brackets.
The virus containing the enhancer 92- 1 is the predominant virus in tumor 92. The binding
site for the factor MZF- l is found at the end of the first direct repeat in enhancer 92-
(Figure 9). None of the other isolated enhancers or the injected virus contained the MZF-
binding site in the putative enhancer sequences. Note that there is an MZF- l binding site in
the region between the enhancers and CCAA T. These three U3 regions were similar by
Blast search with two MCF viral U3 regions , MCF 247W (84 85) and MCF-Tikaut (28).
MCF 247W is a leukemogenic MCF virus from a spontaneous thymoma of an AKRJ
mouse and contains a 105 bp duplicated enhancer. MCF-Tikaut is a leukemogenic MCF
virs cloned and sequenced from a region upstream of c-myc in a reverse transcriptional
orientation and was shown to induce increased c-myc gene expression. MCF-Tikaut
contains a 100 bp duplicated enhancer.
Group III is more similar to the virus MCF 1233 than to the injected virus. Relative
to MCF 1dr supF these U3 regions contain mutations around the E-Box and NF- 1 binding
site. The enhancers contained in this group mayor may not have duplications. In this
group there are four enhancers (95- , 106- , 106-2 and 106-3) (see Figue 7 and 10). The
first two enhancers, 95-3 and 106- , appear to be trcated enhancers containing sites for
only LVb, Core, E-Box, NF 1 and GRE and adds a NF-KB site at the 5' end. The third and
four enhancers, 106-2 and 106- , contain duplicated versions ofa similar 82 bp enhancer
element seen in 106- 1. The first duplicated region is preceded by C/EBPbeta, L Vb and
GRE/E47 sites followed by the 82 bp element of 106- 1. The second duplicated region
contains only the 82 bp enhancer element seen in 106- 1. A Blast search homology with
this group of enhancer elements shows that they closely resemble the virus MCF1233.
MCF1233 is an oncogenic MuLV from C57BL mice that induces both T and B lymphomas
(138).
Cloning of integration site. The proviral U3-c-myc integration-junction fragment from
tumor 106 was amplified using a primer homologous to the U5 region of the L TR (primer
3B), with a c-myc specific primer (primer TEF 85) located in the upstream promoter region.
The high fidelity polymerase Pfu was used for amplification. A 787 bp product containing
most of the L TR including the rearanged supF gene and 139 bp of c-myc integrated 520 bp
upstream of c-myc exon 1 was generated. A Blast sear h using the 139 bp portion of the
PCR product identified 100% homology to the murne c-myc (accession # M12345 , bp
998- 1136) proto-oncogene (data not shown)(28). The enhancer sequence obtained from
this cloned integration site contains duplicated sequences from the enhancer region and
corresponds to both of the fragments 106-2 and 106-3 (Figue 11). There are four base pair
differences between each of the two cloned enhancers (106-2 and 106-3) and the integration
junction sequence (l06-Int). The differences between the two cloned enhancer elements
and the integration junction site may be the result of cloning arifacts.
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Chapter III-Figue 11. Sequence alignent of tumor 106 integration site and two
isolated enhancer elements from tuor 106. Underlined sequence is homologous to
the c-myc promotor region (accession # M12345, bp 998-1136). Boxed region is the
portion of the supF tag that was retained.
Linkage of supF tagged L TR' s to c-myc in tumor DNAs. To identify the
predominant virus L TR integrated next to c-myc tumor DNAs were PCR amplified with
the L TR primer 3 and either myc primers A, B , or D (Figure 12A). One half of each
reaction product was digested with the restrction enzmes Dra I and Nhe 1. Dra I cuts in
the U3 region of the L TR and removes a 171 bp product to the end of the L TR primer.
The Nhe I site lies 29 bp 3' of the start of U3 , just upstream of the supF gene in U3 (Figure
12A). The other half of each reaction was left undigested. The uncut PCR products are
predicted to vary in size depending on where the proviruses integrated with respect to the
c-myc primer used in the amplification reaction, as well as alterations within the enhancer
sequence or supF gene rearrangements or both. Both undigested and digested amplification
products were electrophoresed, Southern blotted, and hybridized with a supF specific
probe (Figue 12B). After exposure of the autoradiograph, the blot was strpped, analyzed
by phospho-imager for complete probe removal , and re-hybridized with a c-myc specific
probe (Figue l2C). MCF (ldr) supFproviral LTRs would produce a 498 bp supF specific
band when cut with Dra I and Nhe 1. Variations in size of the digested PCR product would
either be due to alterations within the enhancer sequence, the supF gene or other sequences
in that region. Sequence analysis of92- , 106- , 106-3 and 106-Int, indicated that the supF
tag from some enhancer regions underwent gene rearangements. This most likely was due
to the strong secondar strctue and high GC content causing pauses in the DNA
polymerase durng reverse transcription (36 , 56).
supF
Dra I 527
CAA T 532
T A 586 
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Chapter III-Figure 12A. Diagram of MCF(ldr)supF LTR. Priers used for
PCR amplification are shown with small arrows. Positions of 
Nhe I and Dra restrction sites are shown. Numbers next to the marked sites indicate theirposition relative to the 5' end of U3.
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Chapter III-Figure 12B. Southern blot of PCR products probed 
with supF.
Tumor DNAs or normal thymus DNA are indicated above each pair of
lanes along with the PCR primers used in each reaction. 3 is the LTR 
prier. A, B, C, D are the four upstream c-myc priers. U= uncut,
C= digested with Dra I and Nhe 
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Chapter III-Figure 12C. Southern blot of PCR products probed with c-myc.
Tumor ONAs or normal thymus DNA are indicated above each pair of
lanes along with the PCR primers used in each reaction. 3 is the LTR 
primer. A, B, C, 0 are the four upstream c-myc primers. U= uncut,
C= digested with Dra I and Nhe 
Three of the four analyzed tumors (#92
, 95 , 98) hybridized weakly with the supF
probe. In this experiment, amplification products from tumor 106 did not hybridize with
the supF probe. This is most likely due to 
a rearranged supF tag or inadequate
amplification. The integration site cloned from tumor 
106 included c-myc sequence and a
rearranged supF tag (Figue 11). Tumor 92 contained a 1250 bp amplification product (92-
3B) that hybridized with supF. The size of this amplification product was reduced to 620
bp after digestion with Dra I and Nhe I and hybridization with the 
supF probe (Figue l2B
lanes 1 and 2). The 620 bp fragment that hybridizes 
with supF corresponds in size to the
enhancer fragment isolated from tumor 92 that contains a 134 bp duplication (Figues 9 and
14). When the same blot was strpped and reprobed with c-myc the full-length undigested
fragment hybridized with the probe. As there are no known 
Nhe I or Dra I site in the 1.5
kbp region upstream from 
c-myc exon 1 (accession#M122345 , (28)), the digested fragment
should be the size of the c-myc gene from the myc primer to the integration site plus 29 bp
from the end ofU3 to the Nhe I site. The c-myc probed blot (Figue 12C , lanes 1 and 2) of
tumor 92 shows an undigested product of approximately 1250 bp along with multiple
digested products, the strongest of which is approximately 620 bp. 
The undigested c-myc
positive product is approximately the same size as the 
supF probed product as expected.
The less intense bands in the digested sample may be the result of mispriming of the PCR
reaction or a Dra I or Nhe! site near the integration site or an additional integration in a
minor population of tuor cells. This data supports the conclusion that the cloned PCR
product from tuor 92 is the predominant enhancer fragment integrated near c-myc.
Tumor 95 showed by Southern blot a single weak 
supF positive band in the uncut
reaction of approximately 1000 bp (Figue 12B , lane 3). No band was observable in the
digested reaction (Figure 12B , lane 4). It is diffcult to accurately predict which of the
cloned enhancer products from tumor 95 is the most intense band. The enhancer fragment
95-4 was an isolated PCR product that contains a nearly intact 
supF gene by sequence
analysis. The other three enhancer fragments from tumor 95 (95- 95-2 and 95-3) do not
contain sequence for the supF gene. The c-myc probed blot of tumor 95 shows two distinct
products in the undigested sample (Figue 12C , lane 3). The more intense band is
approximately 1000 bp in size. This size is similar the band seen in the 
supF probed blot.
The results for tumor 95 are not definitive as to which is the predominant enhancer
integrated near c-myc.
Tumor 98 showed by Southern blot a single supF positive band in the undigested
lane of approximately 950 bp in PCR reactions using either myc-A or myc-B primer with
LTR 3 primer (Figue l2B , lanes 5 and 7). Upon digestion the band was approximately
600 bp in size (Figue 12B , lanes 6 and 8). The two different c-myc primers should bind to
sequences 505 bp apar in the region upstream of c-mycexon I. The myc primers should
yield very different sized PCR products in this amplification reaction. The approximately
600 bp product is larger than the predicted 498 bp product expected if the predominant
enhancer were 98- 1. If 98- 1 is not the predominant enhancer integrated near 
c-myc in tumor
, it is unclear what is the sequence of the other enhancer. It is also unclear what role the
enhancer 98-1 may play in leukemogenesis, if any.
"-.
Tumor 1 06 did not show a supF positive band by Southern blot even after a long
exposure. The rearranged supF tag seen in the cloned integration site from tumor 106 would
be predicted to poorly hybridize with the radio- labeled supF probe. The c-myc probed
Southern blot of tumor 106 using the primer pair L TR-3 and myc-B shows a major band
approximately 1400 bp in size and two minor bands approximately 1500 bp and 600 bp
(Figue 12C, lane 9). The three bands can not be correlated with any of the cloned enhancer
products because no supF positive signal appears on the supF probed Southern blot. Upon
digestion with Dra I and Nhe I the major c-myc positive band is reduced in size by
approximately 110 bp (Figue 12C , lane 10). All of the enhancers in this study contain
restrction enze sites for Dra I and Nhe 1. This reduction in size does not correspond to
the size enhancer that would be predicted from either the injected virus or any of the
enhancers isolated to date. The c-myc positive bands may be the result of other non-supF
containing proviral integrations or PCR arifacts. After a long exposure, the c-myc probed
Southern blot of tumor 106 using the primer pair LTR-3 and myc-D shows a single band
approximately 1400 bp in size in the uncut sample (data not shown). Upon digestion with
the restrction enzes Dra I and Nhe I a single band approximately 900 bp in size is
faintly visible (data not shown). The change in size corresponds to an approximately 500
bp Dra I-Nhe I enhancer fragment. The enhancer fragment isolated from the cloned
integration site from tumor 106 would yield a fragment 466 bp in size after Dra I-Nhe 
digestion. This is very close in size to extrapolated 500 bp product from the 106-
amplification. The high sequence homology of the two duplicated enhancer fragments 106-
2 and 106-3 along with the duplicated enhancer from the cloned integration site from tumor
106 suggest they are all derived from the same duplicated enhancer and may be just PCR
and or cloning varants of one another. These data in conjunction with the cloned
integration site sequence data support the conclusion that the predominant enhancer
fragment integrated near c-myc is the duplicated 82 bp enhancer fragment contained in 106-
, -
3 and the 106-integration site.
"it
DISCUSSION
The hypothesis that I have tested was that specific sequence alterations and
enhancer duplications are selected in proviral integrations proximal to c-myc in tumors of
AKRJ mice. Duplicated enhancers are a hallmark for MCF induced leukemogenicity (57
, 75 , 88 , 99, 147). I have examined the sequence changes that occur in the MCF Idr
supF enhancer region in proviral L TRs durng leukemogenesis. Four early tumors that
contained a rearanged c-myc locus also contained viral U3 regions with various sequence
changes. Although the proviruses integrated near c-myc in two late tumors did not
accelerate leukemogenesis, they stil may playa role in leukemogenesis and are more
likely to be MCF virses that were generated durng the pre- leukemic period (153). The
four early tuors that have provirses integrated near c-myc are more likely to contain
proviruses that are directly involved in acceleratig leukemogenesis.
To begin to understad what specific role the enhancers that have integrated near
c-myc might play we must be aware of the basic concepts of transcriptional regulation
including; chromatin remodeling, histone acetylation, nuclease sensitivity, strctue of
active domains, gene competition, enhancer-promoter interactions, DNA looping, and
boundar elements.
In chromati remodeling, regions of the genome that contain fewer
transcriptionally active genes appear to have a higher level of chromatin condensation
(15). The condensation is thought to prevent non-specific gene activation by limiting the
accessibility of transcription factors. This is demonstrated by the decreased sensitivity
of the condensed regions to DNase I digestion. Unfolded chromatin has historically been
described as a lO-nm chromatin fiber, or ' beads-on-a-strng . This view was based on
early observations from electron micrographs of chromatin spread at low salt
concentration (159). At a physiological salt concentration inside the nucleus chromatin
incubated with moderately acetylated core histones- forms a 30-nm chromatin fiber (49
164).
Core histone proteins contain an amino terminal tail domain that lies on the
, outside of the nucleosome. The tail domain interacts with regulatory proteins and DNA.
The tail domains are lysine-rich and are the tagets for acetylation. Acetylation greatly
reduces the affnity of the histone H4 tail for DNA (76, 176). Chromosomal replication
and repair requires a molecular chaperone that shares a subunit with specific histone
acetyltransferases and deacetylases (173 , 174). In addition the adenovirus oncoprotein
EIA has been shown to modulate the interactions between acetyltransferases (120
, 190).
The chicken globin domain is associated with an increase in levels of histone acetylation
and with depletion of the linker histone HI (68 81). The pattern of hyper acetylation
ends where the transitions from nuclease sensitivity to insensitivity occur. These
modifications are thought to lead to a more open chromatin strctue by contrbuting 
the unolding of chromatin from a more condensed state. Acetylation of histone H4
appears to playa primary role in the strctual changes that mediate enhanced binding of
transcription factors to their recognition sites within nucleosomes (175).
Some promoters compete with each other for enhancer activation (121). Foley
and Engel in experiments with the embryonic to adult globin gene switch in chickens
found that the enhancer provides a single limiting activity for which the two promoters
compete (51). Ohtsuki et al showed that TATA-containing promoters might interfere
with activation ofTATA-less promoter s (121).
Locus Control Regions (LCR) are defined in transgenic assays as directing high-
level , tissue-specific expression of linked genes at all sites of integration (63
, 106). In the
chicken globin LCR the data suggests that expression of the adult globin gene be
prevented durg earlier developmental stages by a competitive advantage of the more
proximal €- and y-globin genes (40, 157).
In the model for DNA looping, a highly specific arrangement of interacting
proteins is organized into a strctue termed the enhanceosome. The enhanceosome is
unique combination of activator proteins in a tightly clustered formation that promotes
their interaction and cooperative binding to DNA (16
, 158). The formation of the
enhanceosome facilitates the synergistic assembly of the transcriptosome or pol II
preinitiation complex (16, 158). The enhanceosome is dependent on both the spatial
organization of the activator protein binding sites on the naked chromatin and the stereo-
specific interaction of the activator protein to bend the DNA into complexes with the pol
II transcriptional machinery. Thanos and Maniatis demonstrated that a 6 bp insertion
into the human interferon- (IFN- ) enhancer significantly disrupted the enhancer
activity. However, when a 10 bp insertion which restores the normal helical phasing was
tested, the enhancer activity was restored (158). The duplication of the enhancer
elements seen in our experiments and others may improve the helical phasing of the
,..
transcription factor-binding sites initiating a more active transcriptosome complex. A
pathway in which the duplication of enhancers may facilitate leukemogenesis is by
enhanceosome formation.
Chip is a ubiquitous nuclear protein that binds numerous sites on all chromosomes
(112). Chip and its mammalian homologues interact with and promote dimerization of
nuclear LIM proteins (163). The experimental evidence suggests that the Chip family of
proteins acts primarily to crosslink other diverse proteins together (7
, 112). It appears
that Chip facilitates enhancer organization of the intervening sequences to allow enhancer-
promoter interactions to occur (15). Vertebrate homo logs of Chip interact with LIM
domains of nuclear proteins (112). LIM domains are zinc-finger motifs involved in a
varety of protein-protein interactions (7, 112). LIM domains are capable of binding a
novel RIG-H2 zinc-finger protein, Rlim (for RIG finger LIM domain-binding protein),
which acts as a negative co-regulator via the recruitment of the Sin3A/istone de acetylase
corepressor complex (8). Rlim is a novel corepressor that recruits histone de acetylase-
containing complexes to the LIM domain (8).
An insulator either blocks or reduces activation of a promoter when positioned
between it and the enhancer (53 , 170). Enhancers that are separated from the
promoter by the insulator fail to activate or activate more weakly. Insulators have been
well studied in Drosophila and in the chicken. The globin locus control region is the
best-studied vertebrate insulator element (23). The insulator is directional and fuctions
by alterig the chromatin strctue over the promoter element of the globin locus
control region. It also functions in the Drosophila indicating it operates by a conserved
mechanism. Insulators do not compete with promoters for recruited basal transcription
factors (55, 121). Insulators interfere with mechanisms supporting enhancer-promoter
communication.
A question that needs to be answered is what is the mechanism for enhancer
activation of c-myc in retrovirally induced tumors. Based on the available evidence from
this work and the work of others along with the available knowledge of enhancer-
promoter activation we can propose several models or hypothesis for the deregulation of
c-myc gene expression. One model for the c-myc gene activation may be that the
integration upstream of c-myc disrupts an insulator element found in that region. The
evidence that the majority of viral integrations from tuors are found in a small region
approximately 2 kb upstream of c-myc supports this hypothesis. If an insulator element
is disrupted then the viral enhancer may be in a favorable location to activate the c-myc
promoter. Another model for the c-myc gene activation may be that the viral L TR region
contains binding sites for Chip proteins or homologues. The Chip proteins may facilitate
the recruitment Lim nuclear proteins as well as other transcription factors. The Chip
proteins can then help to position the enhancer elements into a favorable position to up-
regulate the c-myc promoter. Evidence for this hypothesis is supported by the fact the
majority of proviral integrations occur in a reverse transcriptional orientation. The more
distal position of the enhancer elements in the 5' L TR may allow easier interaction
between Chip proteins and the viral enhancer and c-myc promoter elements. An
additional model for the c-myc gene activation may be that the viral enhancer elements
contain binding sites for transcription factors that recruit histone deacetylases that affect
the chromatin strcture of the region. This action may disrupt a normal locus control
region allowing the access and positioning of the enhancer elements with the promoter and
basal transcription machinery. Further examination ofthe c-myc locus control region as
well as DNase I hypersensitivity after viral integrations in the region will be required to
support this hypothesis.
The sequence data from the groups of enhancers I have identified along with the
presence or absence of predominant enhancer tyes in tumors provides evidence for the
requirement of enhancer duplication in leukemogenicity. I have graphically represented
the varous enhancer regions and aligned them with the known transcription factor binding
sites found in MCF Idr supF (Figue 7). The enhancer regions isolated from the four
tumor DNAs have retained the essential leukemogenic elements of L Vb, core, NF - 1 and
GRE (57). It is importnt to note that three (#92 , 98 , 106) of the four tumors contained
supF tagged viral enhancers that were members of a single group. Tumor 95 contained
enhancers similar to all three groups. This does not mean that the thee tumor DNAs do
not contain other proviral enhancer elements that may have contrbuted to
lymphomagenesis. It also does not imply that a specific enhancer or enhancer group is
the primar inducer of lymphomagenesis in these tumors. The enhancer fragment 98-
isolated from tumor 98 having four base changes with only one base pair change that
maintains an NF-KB binding site is very homologous to the weaky leukemogenic injected
virs. The tuor DNAs that gave rise to a single group of enhancers are most likely due
to a monoclonal tuor versus a polyclonal tumor for tuor 95 (97, 153). The isolation of
IF'
more than two enhancers from a single tumor DNA cannot be explained by both alleles
having virus integrations. The presence of two or more enhancer families is most likely
due to polyclonally derived tumor DNAs (97
, 153). A polyclonal tumor is derived from
different cell populations growing together to form a tumor mass. Several of these
different cell populations may have been infected with different enhancer containing
retroviruses. The different enhancer elements can then be amplified from a single tumor
DNA.
Enhancer elements without duplications or major sequence changes from the
injected virus were isolated from two of the tumors (#95 and #98) in this study. Neither
enhancer appears to be the predominant viral enhancer integrated near 
c-myc. This data
suggests that single enhancer elements that do not contain significant sequence changes for
additional transcription factor binding sites may playa limited role in leukemogenesis.
The other seven enhancers that were identified were segregated into two groups based on
their sequence homology and organization of potential transcription factor binding sites.
Three enhancer fragments were isolated from tumor #106. The cloned integration site
data suggest that 106-2 and 106-3 were isolated from the same integration site and the
sequence differences were the result of cloning arifacts. The sequence homology of 106-
1 to 106-
, -
3 suggests the enhancer fragment 106- 1 may either be a trcated version of
106-
, -
3 or a variation that has not undergone enhancer duplication. The duplicated
enhancer fragment 106-
, -
3 appears to be the predominant species integrated near c-myc.
Tumor #95 exhibited a unique mixtue of enhancer sequences. It is the only tuor that
contained products from all three families of enhancers. In a recent analysis by Stakey et
al on the tumorigenic potential ofa recombinant retrovirus containing sequences from
Moloney-MuL V (Mo-MuL V) and Feline Leukemia Virus (FeL V) they repeatedly
isolated more than one unique enhancer sequence from an individual tumor DNA (148).
An unexpected finding is the near identity in sequence of enhancer 95-3 with the three
enhancers from tumor 106. Even though enhancer 95-3 is not duplicated it may be either
trcated version or more likely part of an enhancer region that is frequently duplicated.
The frequency that this enhancer region was isolated in this analysis suggests a role in
leukemogenesis.
There does not appear to be a conserved sequence for a transcription factor
binding site that is created between the enhancer duplications. What might be some other
causes for the increased pathogenicity seen in viruses with duplicated enhancers? A
possible cause may simply be increased numbers of transcription factor binding sites. In
table 2 I have summarzed the predicted number of transcription factor binding sites for
the enhancers analyzed in this study as well as the enhancer from the injected virus MCF
Idr supF and from MCF 247W. It is not known whether increased numbers of
transcription factor binding sites in the enhancer region leads to a more leukemogenic
virs. Based on the conserved organization and sequence of the enhancer that are created
in vivo makes the simple idea that increased numbers of factor binding sites alone having a
leukemogenic effect highly unikely.
What is the common factor in each of the isolated enhancer products? All 
of the
mutations or duplications occur in a region where the binding sites for L Vb
, core, E-
boxI- , and GRE/E7 are clustered together. This region contains highly conserved
motifs among murine type C retroviruses (57). It is important to note that there may be
many subtle changes that occur during the enhancer duplication event that add greatly to
the leukemogenic phenotye observed. Single base changes that occur in areas of high
homology and are conserved among families of viruses are hallmarks for important
transcription factor binding sites (57, 79 , 91 , 96 , 146). Some examples of these changes
among families are shown in Figure 7 and 10. The base changes clustered around C/EBP
beta and the region immediately 5' shows conservation of the changes among families
surounded by ubiquitously conserved bases among all families. The proximity to known
transcription factor binding sites like GRE/E47 and NF-KB make the cluster of nucleotide
changes attactive targets for speculation on their role in enhancing leukemogenesis.
These may be the areas of specificity that the enhancers have gained that distinguish
themselves biologically. Golemis et al compared the sequences of32 tye C murie
retroviruses and found a strking conservation in the region 
surounding L Vb and core.
Golemis et al and others found variations outside the core enhancer framework might
contrbute to the distinct biological properties conferred by the enhancers (13 , 147
162). Mutations in the core motif in MoMuL V have been shown to alter the disease
specificity from thymic leukemia to eryoleukemia (147). All of the enhancers isolated
in our study contained intact L Vb and core regions either singly or duplicated. Our core
sequences were homologous to most MCF enhancer core sequences (Figue 7). The
enhancers that were duplicated all contained duplications of this region. Many 
of the
alterations in sequence occured in the region just upstream from L Vb and core. The
alterations frequently involved the addition of binding sites for the transcription factors
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GRE/E47 and lor NF-KB. Zaiman et al identified critical c-myb and core binding sites in
the SL3-3 retroviral enhancer (194). When mutated
, transcriptional activity of the viral
enhancers in T -cells in vitro was reduced along with the leukemogenicity in vivo. It may
be that the newly created GRE/E47 and/or NF-KB binding sites playa direct role in the
regulation or specificity to the duplicated enhancer region.
In a paper by Madisen et al. they examined the mechanism by which a cassette
containing four DNase I-hypersensitive sites (HSI234) of the IgH locus functions as an
enhancer-locus control region and deregulates transcription of linked 
c-myc genes. In c-
myc genes become juxtaposed to immunoglobulin heavy-chain (IgH) sequences
, resulting
in aberrant c-myc transcription. They showed that translocated c-myc alleles that retain
the first exon exhibit increased transcription from the normally minor 
c-myc promoter, PI
and increased transcriptional elongation through inherent pause sites proximal to the
major c-myc promoter, P2. In addition they showed that the enhancer-locus control region
of the 3 'Ca region IgH locus directs a deregulated expression of linked 
c-myc genes in BL
and plasmacytoma cell lines. They also showed that the HS1234 enhancer-LCR mediates
a widespread increase in histone acetylation along linked 
c-myc genes in Raji BL cells. The
increase in acetylation was not restrcted to nucleosomes within the promoter region but
also was apparent upstream and downstream of the transcription start sites as well as
along vector sequences. They showed that general histone hyperacetylation induced by
the de acetylase inhibitor trchostatin A (TSA) differentially activates transcription from
the P2 promoter of the control compared to the enhancer-
linked c-myc genes and inhibits
It. .
PI transcription from HS 1234- linked templates. These results suggest that the HS 1234
enhancer stimulates transcription of c-myc by a combination of mechanisms. Whereas
HS 1234 activates expression from the P2 promoter through a mechanism that includes
increased histone acetylation, a general increase in histone acetylation is not suffcient to
explain the HSl234-mediated activation of transcription from PI (102). Gene induction
is frequently accompanied by chromatin reorganization both within regulatory regions and
downstream of the transcription start site (150, 154, 189). Might a similar mechanism be
occurg in MCF induced c-myc deregulation. Do the proviral genomes that integrate
near c-myc contain other elements that function as locus control regions? If so , they may
effect the more generalized mechanisms that govern 
c-myc regulation and may begin to
explain some of the observed differences in tumor formation that cannot be attbuted
strctly to enhancer activity.
In sumary, the unique formation of enhancer duplications observed near 
c-myc 
virally induced tumors follows specific patterns. Two unique families of enhancer
duplications that were shared among different tumors were identified. The individual
families exhibited strg sequence homology and a conserved organization of
transcription factor binding sites while developing in different tumors. The development
of these enhancers into conserved families suggests a selective role for their formation.
Examination of the specific activities of the enhancers individually and as group units wil
greatly aid in our understading of their formation and their role in tuor development.
!I.
Chapter IIl- TABLE 2. U3 Transcription Factor Binding Site Summary
C/EBP LVb Core box/ GRE/ NF - KB
beta NF- E47
MCF 247 W
MCF (ldr)supF
98- 1 (1dr)
95-4 (ldr)
92- 1 (2dr)
95- 1 (2dr)
95-2 (2dr)
95-3 (ldr)
106- 1 (ldr)
106-2 (2dr)
106- 2dr
CHAPTER IV
SUMMARY AND CONCLUSIONS
In chapter Il a new packaging cell line was created that packages defective retroviral
vectors into retroviral particles that have the polytropic MCF envelope protein on their
surace. This cell line was used as a tool to investigate the ability of MCF viruses to
transduce human cells for their potential use in human gene therapy. The MCF viruses
successfully transduced moderate numbers of human cells (14% fully supportive, 18%
moderately supportive). The xenotropic viruses successfully transduced the majority of
human cells (87.5% fully supportive). Both virus groups interfered with super-infection by
the other virus group on two chronically infected cells lines. These data provide evidence for
the use of a single receptor on human cells by both polytopic and xenotropic virus groups.
It is unclear as to the cause of the varation in infectability of the human cells by the different
virs groups. This may be the result of amino acid differences in the binding site region of the
envelopes of both virus groups. The xenotropic virus may exhibit a stronger affnity for the
receptor than polytopic viruses. Conversely, there may be an unown co-receptor utilized
durng infection by one or both virus groups.
Three different laboratories recently completed cloning of the polytopic and
xenotropic receptor gene (10, 156 , 191). The receptor gene used by both polytopic and
xenotropic virus groups has been designated either Sygl (related to suppressor of yeast 
deletion) or XPR1 (xenotropic and polytopic retrovirus receptor) (10 , 156 , 191). Yang et al
used MCF-BAG ( galactosidase) and MCF-NEO (Neomycin) virus stocks that I prepared
for them from my packaging cell lines to clone the MCF receptor gene. The two other
laboratories used xenotropic-enveloped viruses to identify the same receptor gene. As
studies of SygllXPRI continue and the function becomes known then the effect of MCF
envelope binding with the receptor can be studied further. If the receptor functions in a G
protein-coupled signal transduction pathway or some other cytokine-dependent signalling
pathway the effect of the MCF envelope-receptor interaction can be studied in detail. The
role this interaction plays in growth factor independent cell growth and/or leukemogenesis can
begin to be identified.
The MCF packaging cell line is a useful tool for the study of MCF viruses and their
receptor usage, but a poor candidate for gene therapy uses. The xenotropic virus may be an
alternative candidate for fuher testing as a tool for human gene therapy.
In chapter III I tested the alterations and duplication events that occur when a tagged
MCF virus containing a single enhancer element is injected into newborn AKRJ mice and
isolated from tumor DNA. Our original hypothesis was that specific sequence alterations
would occur in the region between the enhancer duplications that are commonly found in
MCF induced tumors. I theorized that a unique binding site is created at the duplication
junction, which is directly involved in accelerating the leukemogenesis. To test our
hypothesis Southern blotting and PCR analysis of 31 tumor DNAs was used to determine
the presence of supF tagged virus, the presence of a rearged c-myc gene, and the presence
of supF tagged proviral DNA integrated near the c-myc gene locus. Nine proviral L TRs
integrated near c-myc from four animals were PCR amplified, sequenced, and or cloned. All
of the amplified LTRs contained enhancers with varing modifications. All of the enhancer
elements were from proviruses that integrated in a reverse orientation with respect to c-myc
gene expression. Two of the isolated enhancer fragments contained only a few base changes
whereas the majority contained various duplications of different sizes that encompassed
different transcription factor binding sites. The duplicated enhancer regions contained
duplications from 82- 134 bp in length. One tumor contained a proviral enhancer with only 5
bp changes relative to the injected virus. The other three tumors contained proviral enhancers
with various size duplications and additional transcription factor binding sites. One junction
sequence encompassing a duplicated enhancer region and 139 bp of the 
c-myc gene locus was
PCR amplified, cloned and sequenced. A search of the curent transcription factor databases
showed no known transcription factor binding site sequences were created at the junction of
the enhancer duplications. The common motif of L Vb
, core, NF - 1 and GRE transcription
factor binding sites was conserved thoughout the isolated enhancers. Most of the enhancer
elements contained additional NF-KB and/or GRE sites in close proximity to the conserved
L Vb-core region. These results support the hypothesis that additional NF-KB and/or GRE
binding sites cooperatively interact with the conserved GRE-NF- LVb-core motif in c-myc
induced leukemogenesis. In addition, two unique groups of enhancers were identified. The
two groups contained enhancers isolated from different tumors that displayed sequence
homology and transcription factor binding site organization unique to each group.
The role that enhancers play in the development of leukemogenesis is not entirely
clear. They may increase the ability of the virus to replicate in target tissue (186). If a
replicative advantage exists it may allow the virus to' outgrow other viruses if suffcient
rounds of replication occur (26 , 155 , 185). Enhancers may affect the expression of the
recombinant envelope protein that may stimulate cellular proliferation (94
, 165). Enhancers
may activate cellular proto-oncogenes located nearby after integration (28
, 114 , 122 , 127).
The conclusions are that the unique formation of enhancer duplications observed near
c-myc in virally induced tumors follows specific patterns. These patterns may govern the
formation of enhanceosome complexes and synergistically the pol Il preinitiation complex.
One pattern was the identification of two unique groups of enhancer duplications that were
shared among different tumors. The individual groups exhibited strking sequence homology
and a conserved organzation of transcription factor binding sites while developing in different
tumors. The development of these enhancers into conserved groups suggests a selective role
for their formation. It wil be useful for futue experiments to determine whether there are
few clusters of enhancer groups or many more. In addition, whether these groups are found
integrated proximal to c-myc only or do these same groups occur integrated near other proto-
oncogenes. These data should greatly aid our understanding of the biological model of
leukemogenesis.
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